Abstract:Background: Primary mediastinal germ cell tumors (PMGCT) represent a rare but sometimes highly aggressive type of mediastinal tumors. The current prognostic models for PMGCT are insufficient. This study was undertaken to establish and validate an individualized nomogram for predicting the overall survival (OS) of patients with PMGCT. Methods: We conducted a retrospective analysis of patients with PMGCT diagnosed between 2000 and 2018 in the Surveillance, Epidemiology, and End Results (SEER) database in the United States. Clinical variables included surgery subtype, gender, treatment regimens, age, histology, tumor size, stage, chemotherapy, radiation, race, and survival-related information. The main outcome measure was survival duration. The Kaplan-Meier method along with the log-rank test were utilized to estimate the OS. Independent prognostic factors were identified by performing the univariate and multivariate Cox proportional hazards regression analyses, from which an individualized nomogram was constructed to predict 3-, 5-, and 10-year OS of patients with PMGCT. The concordance index (C-index) and calibration curve were used to verify the discrimination and accuracy of the nomogram. Results: A total of 845 patients with PMGCT were recruited from the SEER database and further randomly assigned to a training set (n=635) and a validation set (n=210) at a ratio of 7:3. The 3-, 5-, and 10-year OS for overall PMGCT was 70.0%, 67.1%, and 63.9%, respectively. Cox regression analysis indicated that age, tumor size, stage, chemotherapy, radiation, histology, and surgery type were as independent factors for OS in patients with PMGCT (P<0.05). An individualized nomogram for OS was constructed utilizing these variables, with the C-index of 0.714 [95% confidence interval (CI): 0.695 to 0.743] and 0.756 (95% CI: 0.735 to 0.787) in the training and validation groups. Moreover, good levels of agreement were observed according to the calibration curve between the predicted and actual 3-, 5-, and 10-year survival rates both in the training and validated cohorts, showing that the model could accurately predict patient prognosis. Conclusions: This study documented the first attempt at establishing and validating a novel nomogram for predicting the 3-, 5-, and 10-year OS probabilities of PMGCT. The prognostic nomogram was demonstrated to have good performance for predicting individualized OS of patients with PMGCT.

Prediction of Survival Prognosis for Spinal Metastasis from Cancer of Unknown Primary: Derivation and Validation of a Nomogram Model.

Development and Validation of a Novel Survival Prediction Model in Patients with Spinal Metastasis from Non-small Cell Lung Cancer.

A Prognostic Nomogram in Patients with Distant Metastasis of Pancreatic Neuroendocrine Tumors: a Population-Based Study.

Prognostic Nomograms for Patients with Metastatic Gastric Cancer: A Large Population-Based Cohort Study and External Validation

A Nomogram Predicting the Prognosis of Renal Cell Carcinoma Patients with Lung Metastases

Novel Nomograms to Predict of Overall Survival and Cancer-specific Survival of Patients of Metaplastic Breast Cancer

Development and Validation of a Dynamic Survival Nomogram for Metastatic Non-Small Cell Lung Cancer Based on the SEER Database and an External Validation Cohort.

Establishment and validation of a novel survival prediction scoring algorithm for patients with non-small-cell lung cancer spinal metastasis

Development and validation of a nomogram for predicting overall survival of patients with cancer of unknown primary: a real-world data analysis

Predicting the Probability of Tumor-Specific Survival in Patients Diagnosed With Primary Tumors in the Spinal Cord Using Nomogram Models

The emergence of new prognostic scores in lung cancer patients with spinal metastasis: A 12-year single-center retrospective study

Establishment and Validation of an Individualized Nomogram for Survival Prediction of Primary Mediastinal Germ Cell Tumors Based on the SEER Database.

Survival Nomogram for Patients with Initially Diagnosed Metastatic Non-Small-cell Lung Cancer: a SEER-based Study

Development and Validation of a Nomogram for Predicting Overall Survival In Synchronous Peritoneal Metastasis of Colorectal Cance

Nomogram model of survival prediction for nasopharyngeal carcinoma with lung metastasis: developed from the SEER database and validated externally

Nomograms to predict lung metastasis in malignant primary osseous spinal neoplasms and cancer-specific survival in lung metastasis subgroup

Prognostic nomograms for predicting long‐term overall survival in spindle cell melanoma: a population‐based study

Development and validation of a nomogram for predicting survival in patients with malignant myofibroblastic tumor

Clinical Features, Risk Factors, and Prediction Nomogram for Primary Spinal Osteosarcoma: A Large-Cohort Retrospective Study.

Which Prognostic Model Best Predicts Poor Prognosis in Patients with Spinal Metastases? A Comparative Analysis of 8 Scoring Systems

Development and validation of nomograms predicting overall and cancer-specific survival for non-metastatic primary malignant bone tumor of spine patients